Cytomegalovirus (CMV) is a highly prevalent virus, with infection rates of >60% in the USA, and much higher in the developing world. In most cases infection is asymptomatic, but infection can be serious in immunocompromised patients, and congenital infection of the fetus may lead to developmental problems in the newborn. In numerical terms fetal infection with CMV is a significantly larger problem worldwide than infection with Zika virus.
With this background the requirement for diagnostic testing for CMV remains a high priority, and significant efforts are also being undertaken to develop a vaccine to prevent CMV infection.
At The Native Antigen Company we have developed a range of CMV products that are suitable for both IVD assay development and for specific vaccine R&D studies. These antigens include preparations from native virus alongside highly purified recombinant proteins expressed in mammalian cells.
Showing all 6 results
We hold good stocks of all our antigens to ensure a rapid delivery service worldwide. We like to be in touch with our customers so please drop us a line or give us a call on +44 (0)1865 595230. To place an order, please email firstname.lastname@example.org and for further information including price inquiries, bulk preparations and contract services email: email@example.com.